Comparative Analysis of Vascular Calcification Risk Factors in Pre-Hemodialysis and Prevalent Hemodialysis Adult Patients: Insights into Calcification Biomarker Associations and Implications for Intervention Strategies in Chronic Kidney Disease

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2024 Apr 26

PMID 38667470

Authors

Marko Petrovic

Voin Brkovic

Marko Baralic

Ivko Maric

Nenad Petkovic

Sanja Stankovic

Natasa Lalic

Dejana Stanisavljevic

Ljubica dukanovic

Visnja Lezaic

Affiliations

Soon will be listed here.

Abstract

This retrospective study aimed to compare risk factors for vascular calcification (VC) between pre-hemodialysis (HD) and prevalent HD adult patients while investigating associations with calcification biomarkers. Baseline data from 30 pre-HD and 85 HD patients were analyzed, including iPTH, vitamin D, FGF 23, fetuin-A, sclerostin, and VC scores (Adragao method). Prevalence of VC was similar in both groups, but HD patients had more frequent VC scores ≥ 6. Pre-HD patients were older, with higher prevalence of hypertension and less frequent use of calcium phosphate binders. Both groups showed similar patterns of hyperphosphatemia, low vitamin D, and iPTH. Fetuin-A and sclerostin levels were higher in pre-HD, while FGF 23 was elevated in HD patients. Higher VC risk in pre-HD patients was associated with male gender, older age, lower fetuin-A and higher sclerostin, lower ferritin, and no vitamin D treatment, while in HD patients with higher sclerostin, FGF 23 and urea, and lower iPTH. Conclusion: Biomarkers could be measurable indicators of biological processes underlying VC in CKD patients that may serve as a potential guide for considering personalized therapeutic approaches. Further studies are needed to elucidate the underlying pathways.

Citing Articles

Understanding Vascular Calcification in Chronic Kidney Disease: Pathogenesis and Therapeutic Implications.

Siracusa C, Carabetta N, Morano M, Manica M, Strangio A, Sabatino J Int J Mol Sci. 2024; 25(23).

PMID: 39684805 PMC: 11642360. DOI: 10.3390/ijms252313096.

References

Wolf M . Update on fibroblast growth factor 23 in chronic kidney disease. Kidney Int. 2012; 82(7):737-47. PMC: 3434320. DOI: 10.1038/ki.2012.176. View

Di Lullo L, Tripepi G, Ronco C, DArrigo G, Barbera V, Russo D . Cardiac valve calcification and use of anticoagulants: Preliminary observation of a potentially modifiable risk factor. Int J Cardiol. 2018; 278:243-249. DOI: 10.1016/j.ijcard.2018.11.119. View

Hou Y, Liu W, Zheng C, Zheng J, Yen T, Lu K . Role of Vitamin D in Uremic Vascular Calcification. Biomed Res Int. 2017; 2017:2803579. PMC: 5329659. DOI: 10.1155/2017/2803579. View

Desjardins L, Liabeuf S, Renard C, Lenglet A, Lemke H, Choukroun G . FGF23 is independently associated with vascular calcification but not bone mineral density in patients at various CKD stages. Osteoporos Int. 2011; 23(7):2017-25. DOI: 10.1007/s00198-011-1838-0. View

Cannata-Andia J, Rodriguez Garcia M, Gomez Alonso C . Osteoporosis and adynamic bone in chronic kidney disease. J Nephrol. 2012; 26(1):73-80. DOI: 10.5301/jn.5000212. View

Yee-Moon Wang A, Akizawa T, Bavanandan S, Hamano T, Liew A, Lu K . 2017 Kidney Disease: Improving Global Outcomes (KDIGO) Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Guideline Update Implementation: Asia Summit Conference Report. Kidney Int Rep. 2020; 4(11):1523-1537. PMC: 6933448. DOI: 10.1016/j.ekir.2019.09.007. View

Persy V, DHaese P . Vascular calcification and bone disease: the calcification paradox. Trends Mol Med. 2009; 15(9):405-16. DOI: 10.1016/j.molmed.2009.07.001. View

Gungor O, Kocyigit I, Yilmaz M, Sezer S . Role of vascular calcification inhibitors in preventing vascular dysfunction and mortality in hemodialysis patients. Semin Dial. 2017; 31(1):72-81. DOI: 10.1111/sdi.12616. View

Hollis B, Wagner C . Normal serum vitamin D levels. N Engl J Med. 2005; 352(5):515-6. DOI: 10.1056/NEJM200502033520521. View

10.

Souberbielle J, Roth H, Fouque D . Parathyroid hormone measurement in CKD. Kidney Int. 2009; 77(2):93-100. DOI: 10.1038/ki.2009.374. View

11.

Isakova T, Xie H, Yang W, Xie D, Anderson A, Scialla J . Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA. 2011; 305(23):2432-9. PMC: 3124770. DOI: 10.1001/jama.2011.826. View

12.

Mancia G, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G . 2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2013; 34(28):2159-219. DOI: 10.1093/eurheartj/eht151. View

13.

Sakaguchi Y, Hamano T, Obi Y, Monden C, Oka T, Yamaguchi S . A Randomized Trial of Magnesium Oxide and Oral Carbon Adsorbent for Coronary Artery Calcification in Predialysis CKD. J Am Soc Nephrol. 2019; 30(6):1073-1085. PMC: 6551769. DOI: 10.1681/ASN.2018111150. View

14.

Qureshi A, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A . Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification. Kidney Int. 2015; 88(6):1356-1364. DOI: 10.1038/ki.2015.194. View

15.

Bisson S, Ung R, Mac-Way F . Role of the Wnt/-Catenin Pathway in Renal Osteodystrophy. Int J Endocrinol. 2018; 2018:5893514. PMC: 5901476. DOI: 10.1155/2018/5893514. View

16.

Kakani E, Elyamny M, Ayach T, El-Husseini A . Pathogenesis and management of vascular calcification in CKD and dialysis patients. Semin Dial. 2019; 32(6):553-561. DOI: 10.1111/sdi.12840. View

17.

Urena P, De Vernejoul M . Circulating biochemical markers of bone remodeling in uremic patients. Kidney Int. 1999; 55(6):2141-56. DOI: 10.1046/j.1523-1755.1999.00461.x. View

18.

Adragao T, Pires A, Lucas C, Birne R, Magalhaes L, Goncalves M . A simple vascular calcification score predicts cardiovascular risk in haemodialysis patients. Nephrol Dial Transplant. 2004; 19(6):1480-8. DOI: 10.1093/ndt/gfh217. View

19.

Damjanovic T, Djuric Z, Markovic N, Dimkovic S, Radojicic Z, Dimkovic N . Screening of vascular calcifications in patients with end-stage renal diseases. Gen Physiol Biophys. 2009; 28 Spec No:277-83. View

20.

Thompson B, Towler D . Arterial calcification and bone physiology: role of the bone-vascular axis. Nat Rev Endocrinol. 2012; 8(9):529-43. PMC: 3423589. DOI: 10.1038/nrendo.2012.36. View